Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer: Performance Is Improving, But Secular Issues Persist (Rating Upgrade) Aug. 23, 2024 4:29 AM ET Pfizer Inc. (PFE) Stock , PFE:CA Stock PFE , PFE:CA 17 Comments 3 Likes KM Capital ...

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

Firstly, let us look at Pfizer’s stock performance in recent years. PFE stock has faced a decline of 15% from levels of $35 in early January 2021 to around $30 now, vs. an increase of about 45% ...

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

Pfizer ( (PFE)) has been popular among investors this week. Here is a recap of the key news on this stock. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment ...

Pfizer is now more focused on innovative drugs and vaccines, analyst says Last Updated: Feb. 4, 2025 at 12:58 p.m. ET First Published: Feb. 4, 2025 at 7:09 a.m. ET Share ...